Latest & greatest articles for sepsis

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on sepsis or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on sepsis and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for sepsis

621. Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. Full Text available with Trip Pro

Risk factors for early onset neonatal group B streptococcal sepsis: case-control study. To quantify risk factors for and the prevalence of early onset group B streptococcal sepsis in neonates in a geographically defined population.Cases were collected prospectively for two years from April 1998 and compared with four controls each, matched for time and place of delivery.The former Northern health region of the United Kingdom.Infants infected with group B streptococcus in the first week (...) of life.The prevalence of early onset group B streptococcal sepsis was 0.57 per 1000 live births. Premature infants comprised 38% of all cases and 83% of the deaths. Prematurity (odds ratio 10.4, 95% confidence interval 3.9 to 27.6), rupture of the membranes more than 18 hours before delivery (25.8, 10.2 to 64.8), rupture of the membranes before the onset of labour (11.1, 4.8 to 25.9), and intrapartum fever (10.0, 2.4 to 40.8) were significant risk factors for infection. Had the interim recommendations

2002 BMJ

622. Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. (Abstract)

Changes in pathogens causing early-onset sepsis in very-low-birth-weight infants. It is uncertain whether the rates and causes of early-onset sepsis (that occurring within 72 hours after birth) among very-low-birth-weight infants have changed in recent years, since antibiotics have begun to be used more widely during labor and delivery.We studied 5447 very-low-birth-weight infants (those weighing between 401 and 1500 g) born at centers of the Neonatal Research Network of the National Institute (...) of Child Health and Human Development between 1998 and 2000 who had at least one blood culture in the first three days of life and compared them with 7606 very-low-birth-weight infants born at centers in the network between 1991 and 1993.Early-onset sepsis (as confirmed by positive blood cultures) was present in 84 infants in the more recent birth cohort (1.5 percent). As compared with the earlier birth cohort, there was a marked reduction in group B streptococcal sepsis (from 5.9 to 1.7 per 1000 live

2002 NEJM

623. Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. (Abstract)

Inhibition of intestinal epithelial apoptosis and survival in a murine model of pneumonia-induced sepsis. Increased intestinal epithelial apoptosis is present in both human autopsy studies and animal models of sepsis. Whether altering gut apoptosis decreases mortality in sepsis induced by pathogenic bacteria outside the gut is unknown.To determine if decreasing levels of intestinal cell death improves survival in a murine model of Pseudomonas aeruginosa pneumonia-induced sepsis.Prospective (...) sepsis. These results suggest that intestinal epithelial apoptosis may play a role in sepsis-related mortality.

2002 JAMA

624. An economic evaluation of activated protein C treatment for severe sepsis

An economic evaluation of activated protein C treatment for severe sepsis Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2002 NHS Economic Evaluation Database.

625. Activated protein C for severe sepsis

Activated protein C for severe sepsis Activated protein C for severe sepsis Activated protein C for severe sepsis Garces K Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Garces K. Activated protein C for severe sepsis. Ottawa: Canadian Coordinating Office for Health Technology Assessment/Office Canadien de Coordination de l'Evaluation (...) des Technologies de la Sante (CCOHTA) 2002: 4 Authors' objectives To summarise the available evidence on activated protein C for severe sepsis. Authors' conclusions - Severe sepsis is a systemic inflammatory response to infection involving organ dysfunction. Severe sepsis is a common cause of death and is associated with a 20% to 56% mortality rate. - Drotrecogin alpha (activated) is a recombinant human activated protein C (rhAPC) approved in the U.S. for the reduction of mortality in adult

2002 Health Technology Assessment (HTA) Database.

626. Opebecan for meningococcal sepsis - horizon scanning review

Opebecan for meningococcal sepsis - horizon scanning review Opebecan for meningococcal sepsis - horizon scanning review Opebecan for meningococcal sepsis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Opebecan for meningococcal sepsis - horizon scanning review. Birmingham: National Horizon Scanning (...) Centre (NHSC). New and Emerging Technology Briefing. 2002 Authors' objectives To summarise the current research on opebecan for meningococcal sepsis. Authors' conclusions - Clinical impact: Meningococcal sepsis is associated with significant morbidity and mortality. Should treatment with opebecan prove to be successful for severe septicaemia in children (up to 900 children in England and Wales) it is possible that the patient group may be widened to include both less severe paediatric disease

2002 Health Technology Assessment (HTA) Database.

627. Afelimomab for sepsis - horizon scanning review

Afelimomab for sepsis - horizon scanning review Afelimomab for sepsis - horizon scanning review Afelimomab for sepsis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Afelimomab for sepsis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging Technology (...) Briefing. 2002 Authors' objectives To summarise the available evidence on afelimomab for sepsis. Authors' conclusions - Clinical impact: The clinical impact associated with the introduction of afelimomab initially appears small and needs further assessment when trial results are fully published. However afelimomab is a new treatment for a patient group that has a very high mortality (50-80%) and any benefit may be clinically significant. - Service impact: It is likely that there will be some service

2002 Health Technology Assessment (HTA) Database.

628. Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial

Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2002 PedsCCM Evidence-Based Journal Club

629. An economic evaluation of activated protein C treatment for severe sepsis

An economic evaluation of activated protein C treatment for severe sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2002 PedsCCM Evidence-Based Journal Club

630. Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis

Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis Prophylactic antibiotic administration reduces sepsis and mortality in acute necrotizing pancreatitis: a meta-analysis Sharma V K, Howden C W Authors' objectives To evaluate the role of prophylactic antibiotics that can achieve minimum inhibitory concentration (...) receiving no antibiotic prophylaxis were excluded. Outcomes assessed in the review The included studies had to report the rates of local pancreatic infections, sepsis and mortality in each treatment arm. How were decisions on the relevance of primary studies made? Both authors independently reviewed each study. Assessment of study quality The authors do not state that they assessed validity. Data extraction The authors do not state how the data were extracted for the review, or how many of the reviewers

2001 DARE.

631. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. (Abstract)

Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. Activation of the coagulation system and depletion of endogenous anticoagulants are frequently found in patients with severe sepsis and septic shock. Diffuse microthrombus formation may induce organ dysfunction and lead to excess mortality in septic shock. Antithrombin III may provide protection from multiorgan failure and improve survival in severely ill patients.To determine (...) if high-dose antithrombin III (administered within 6 hours of onset) would provide a survival advantage in patients with severe sepsis and septic shock.Double-blind, placebo-controlled, multicenter phase 3 clinical trial in patients with severe sepsis (the KyberSept Trial) was conducted from March 1997 through January 2000.A total of 2314 adult patients were randomized into 2 equal groups of 1157 to receive either intravenous antithrombin III (30 000 IU in total over 4 days) or a placebo (1% human

2001 JAMA Controlled trial quality: predicted high

632. Early goal-directed therapy in the treatment of severe sepsis and septic shock. Full Text available with Trip Pro

Early goal-directed therapy in the treatment of severe sepsis and septic shock. Goal-directed therapy has been used for severe sepsis and septic shock in the intensive care unit. This approach involves adjustments of cardiac preload, afterload, and contractility to balance oxygen delivery with oxygen demand. The purpose of this study was to evaluate the efficacy of early goal-directed therapy before admission to the intensive care unit.We randomly assigned patients who arrived at an urban (...) emergency department with severe sepsis or septic shock to receive either six hours of early goal-directed therapy or standard therapy (as a control) before admission to the intensive care unit. Clinicians who subsequently assumed the care of the patients were blinded to the treatment assignment. In-hospital mortality (the primary efficacy outcome), end points with respect to resuscitation, and Acute Physiology and Chronic Health Evaluation (APACHE II) scores were obtained serially for 72 hours

2001 NEJM Controlled trial quality: uncertain

633. Xigris for severe sepsis - horizon scanning review

Xigris for severe sepsis - horizon scanning review Xigris for severe sepsis - horizon scanning review Xigris for severe sepsis - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Xigris for severe sepsis - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). New and Emerging (...) Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on Xigris (previously known as Zovant) for severe sepsis. Authors' conclusions - Clinical impact: The clinical impact associated with the introduction of Xigris may be significant as it is a new treatment for a patient group that has a very high (30-50%) mortality rate. - Service impact: It is likely that there will be some service impact associated with the introduction of Xigris as intensive care staff will need

2001 Health Technology Assessment (HTA) Database.

634. Efficacy and safety of recombinant human activated protein C for severe sepsis. Full Text available with Trip Pro

Efficacy and safety of recombinant human activated protein C for severe sepsis. Drotrecogin alfa (activated), or recombinant human activated protein C, has antithrombotic, antiinflammatory, and profibrinolytic properties. In a previous study, drotrecogin alfa activated produced dose-dependent reductions in the levels of markers of coagulation and inflammation in patients with severe sepsis. In this phase 3 trial, we assessed whether treatment with drotrecogin alfa activated reduced the rate (...) with severe sepsis and may be associated with an increased risk of bleeding.

2001 NEJM Controlled trial quality: predicted high

635. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. (Abstract)

Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Hydroxyethylstarch used for volume restoration in brain-dead kidney donors has been associated with impaired kidney function in the transplant recipients. We undertook a multicentre randomised study to assess the frequency of acute renal failure (ARF) in patients with severe sepsis or septic shock treated with hydroxyethylstarch or gelatin.Adults with severe sepsis or septic shock were (...) -5.83], p=0.026).The use of this preparation of hydroxyethylstarch as a plasma-volume expander is an independent risk factor for ARF in patients with severe sepsis or septic shock.

2001 Lancet Controlled trial quality: predicted high

636. Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis

Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

637. Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock

Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

638. A Randomized, Double-Masked, Placebo-Controlled Trial of Recombinant Granulocyte Colony-Stimulating Factor Administration to Preterm Infants With the Clinical Diagnosis of Early-Onset Sepsis

A Randomized, Double-Masked, Placebo-Controlled Trial of Recombinant Granulocyte Colony-Stimulating Factor Administration to Preterm Infants With the Clinical Diagnosis of Early-Onset Sepsis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

639. High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial

High-Dose Antithrombin III in Severe Sepsis: A Randomized Controlled Trial PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

640. Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. (Abstract)

Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial. rBPI21 Meningococcal Sepsis Study Group. Endotoxin is a primary trigger of the inflammatory processes that lead to shock, multiorgan failure, and purpura fulminans in meningococcal sepsis. Bactericidal/permeability-increasing protein (BPI) is a natural protein, stored within the neutrophil granules, that binds to and neutralises the effects (...) of endotoxin in vitro, in laboratory animals, and in humans. To establish whether a recombinant 21-kDa modified fragment of human BPI (rBPI21), containing the active antimicrobial and endotoxin-neutralising moiety, would decrease death and long-term disability from meningococcal sepsis, we did a randomised, double-blind, placebo-controlled trial of rBPI21 in children with severe meningococcal sepsis.We enrolled children (2 weeks to 18 years of age) presenting to 22 centres in the UK and the USA

2000 Lancet Controlled trial quality: predicted high